Testimonials

Background stories of how others approached and experienced their European Horizon funding trajectory.

RUSTICA - Converting organic residues into bio-based fertiliser products

image of RUSTICA - Converting organic residues into bio-based fertiliser products

Published on | 2 years ago

Programmes Agro-Food, Environment Circular Industries Green Deal

The RUSTICA project obtained funding under Horizon 2020, more in particular under the topic ‘Closing nutrient cycles’.  RUSTICA focuses on demonstration and implementation of circular bio-based nutrient valorisation chains, focusing on waste from the fruit and vegetable agro-food system. The project kicked off in 2021 and will run until 2024. It will use a strong multi-actor approach to co-create both socio-economic and technological knowledge in four case study regions in Europe and one in Colombia. The Flanders-based company DRANCO is one of the project partners and acts as technical project manager for the entire project. DRANCO participates in the project to develop its own technologies, to network and to help make the transition to a more circular based economy.

Read the full article for details 
Other available testimonials

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.